One pill, one time, one dose—and the adherence rate stayed high
Among the many quiet tragedies of modern medicine is the stroke survivor who escapes death only to face a second blow — and a life diminished by dependency. A five-year international trial, anchored in part by Brazil's Unesp, has offered a measured but meaningful answer: a single daily pill combining three familiar blood pressure drugs reduced the risk of recurrent hemorrhagic stroke by 39 percent, not through any dramatic discovery, but through the elegant simplicity of making it easier for people to do what they already knew they should. In a country where stroke claims over 106,000 lives a year and leaves most survivors unable to return to work, the unglamorous act of swallowing one tablet may carry more weight than it appears.
- Hemorrhagic stroke survivors face a grim statistical shadow — one in five will suffer a heart attack within two to five years, making recurrence prevention one of medicine's most urgent unsolved problems.
- The TRIDENT trial enrolled 1,670 patients across 12 countries to test whether combining telmisartan, amlodipine, and indapamide into a single low-dose pill could disrupt that pattern — and after five years, the answer arrived in the New England Journal of Medicine.
- The polypill group averaged 127 mmHg blood pressure against 138 mmHg in the placebo group, translating to 4.6% recurrent stroke versus 7.4% — a 39% risk reduction that extended to other serious cardiovascular events as well.
- The trial's most surprising finding may be behavioral: 86% of patients adhered to the regimen over five years, a rate researchers attribute directly to the one-pill, once-daily design that removes the friction of managing multiple medications.
- With Brazilian winter approaching and stroke incidence rising up to 20% in cold months, clinicians are urging survivors and at-risk patients alike toward the fundamentals — blood pressure monitoring, hydration, movement, and the discipline of daily medication.
Stroke is Brazil's second-leading killer, claiming more than 106,000 lives in 2024. For those who survive, the aftermath is often devastating — seven in ten never return to work, and half require ongoing care. Worse still, survival does not mean safety: the risk of a second stroke or heart attack remains sharply elevated for years.
A five-year international clinical trial called TRIDENT set out to address this recurrence problem directly. Researchers from 61 centers across 12 countries, including Unesp's medical school in Botucatu, enrolled 1,670 hemorrhagic stroke survivors — patients whose blood vessels had ruptured and bled into the brain. Half received a polypill combining three established blood pressure medications: telmisartan, amlodipine, and indapamide, all at low doses. The other half received a placebo. Both groups continued standard post-stroke care.
The results, published in The New England Journal of Medicine, were clear. The polypill group maintained an average blood pressure of 127 mmHg, compared to 138 mmHg in the placebo group. Over roughly two and a half years, 4.6% of polypill patients suffered another stroke versus 7.4% in the placebo group — a 39% reduction in risk. Serious cardiovascular events followed the same pattern: 6.6% versus 9.8%.
Dr. Rodrigo Bazan, the neurologist who led Brazil's participation and heads Unesp's neuroscience department, stresses that the drugs themselves are not new — they are old, off-patent, and well understood. The innovation was consolidation: one tablet, once a day. That simplicity produced something rare in long-term research — an 86% adherence rate sustained across five years. Three separate pills at different times of day would have eroded that compliance steadily. One pill did not.
Unesp's Botucatu campus contributed 18 patients to the trial, supported by the university's stroke unit, clinical research infrastructure, and years of follow-up coordination. As winter arrives in Brazil — a season that historically drives stroke incidence up by as much as 20% through blood pressure disruption and reduced activity — specialists are renewing a familiar call: monitor your pressure, stay hydrated, keep moving, and take your medication. For the tens of thousands who have already survived one stroke, that last instruction may now be simpler to follow than it has ever been.
Stroke kills more Brazilians than any cause except one. In 2024 alone, it claimed over 106,000 lives. Those who survive often don't recover their old lives—seven in ten never return to work, and half become dependent on constant care. The disease carries a cruel arithmetic: once you've had one stroke, your odds of having another climb sharply. Within two to five years, one in five stroke survivors will suffer a heart attack.
This recurrence problem sits at the center of a five-year international study that wrapped up recently with results published in The New England Journal of Medicine. Researchers from 61 centers across 12 countries, including Brazil's Unesp medical school in Botucatu, tested whether a single pill containing three blood pressure medications could change the trajectory for people who'd survived a hemorrhagic stroke—the kind caused by a ruptured blood vessel bleeding into the brain.
The trial, called TRIDENT, enrolled 1,670 patients who met strict criteria: they had to be medically stable, their blood pressure had to remain elevated even on existing medication, and they couldn't have contraindications to any of the three drugs. Half received the experimental polypill—a combination of telmisartan, amlodipine, and indapamide, all at low doses and all already on the market separately. The other half got placebo. Both groups continued their standard post-stroke care.
What happened over those five years matters. The polypill group's average blood pressure settled at 127 millimeters of mercury. The placebo group's stayed at 138. By the two-and-a-half-year mark, 38 patients taking the triple medication had suffered another stroke—4.6 percent of their group. In the placebo group, 62 patients had strokes, or 7.4 percent. The reduction in risk: 39 percent. Other serious cardiovascular events followed the same pattern, occurring in 6.6 percent of the polypill group versus 9.8 percent of those on placebo.
Dr. Rodrigo Bazan, a neurologist who led the Brazilian arm of the research and heads the neuroscience department at Unesp's medical school, emphasizes that the study was safe because the polypill supplemented rather than replaced existing treatment. The real innovation wasn't the drugs themselves—they're old, off-patent, and familiar to any cardiologist. The innovation was putting them together in one tablet, taken once daily.
That simplicity drove something rare in long-term medical research: 86 percent of patients stuck with the medication. Bazan points out how unlikely this is over five years. If patients had to juggle three separate pills at different times of day, many would forget or give up. Instead, one pill, one time, one dose—and the adherence rate stayed high enough to matter. "The efficacy is tied to this technology," Bazan says.
Unesp's Botucatu campus recruited 18 of the trial's 1,670 patients, funneling them from the hospital's stroke unit through the clinical research unit for screening, enrollment, and five years of follow-up visits and phone calls. The university's infrastructure—the pharmacy storing the medication, the staff making periodic contact, the coordination across an international team—made the work possible.
As winter approaches in Brazil, there's a final note worth hearing. Stroke incidence rises by up to 20 percent when temperatures drop, according to health ministry data. Cold weather disrupts blood pressure control, reduces water intake, and encourages sedentary behavior. The specialists' advice is straightforward: watch your blood pressure closely, stay hydrated, keep moving. For the 106,000 Brazilians who will face stroke this year, and the many more who've already survived one, the message is the same—prevention, vigilance, and the unglamorous work of taking your medication.
Notable Quotes
The efficacy has to do with this technology—three drugs in low dose in one pill, taken once a day. Imagine if the patient had to take three different drugs at different times. They'd forget or stop treatment.— Dr. Rodrigo Bazan, neurologist and lead researcher for Brazil
In winter, blood pressure tends to become uncontrolled because the body works differently to stay warm, and people drink less water and become more sedentary. These factors favor stroke occurrence.— Dr. Rodrigo Bazan
The Hearth Conversation Another angle on the story
Why does a pill combining three existing drugs count as innovation?
Because the problem isn't the drugs—it's whether people actually take them. A patient on three separate medications at different times of day will forget or stop. One pill, once daily, changes the math entirely. Over five years, that difference between 86 percent adherence and, say, 60 percent, is the difference between preventing strokes and not.
But the drugs themselves are old. Why not just tell patients to take all three separately?
Because telling and doing are different things. The trial proved that when you remove friction—one pill instead of three, one time instead of multiple—people stay compliant. That compliance is what actually prevents the second stroke.
What surprised the researchers most?
Probably that the effect was so clean. A 39 percent reduction in recurrent stroke is substantial. But also that they could maintain contact with 1,670 patients across 12 countries for five years. That infrastructure itself is rare.
Does this change how doctors will treat stroke survivors in Brazil?
It could, if the polypill becomes available and affordable. Right now it's a proof of concept. But for a country where 70 percent of stroke survivors can't work again, anything that prevents a second stroke is worth taking seriously.
Why does winter matter in this story?
Because stroke doesn't wait for ideal conditions. Cold weather pushes blood pressure up, people move less, drink less water. The same risk factors that caused the first stroke become more active. The polypill helps, but it's not a substitute for staying vigilant when conditions turn dangerous.